Viberzi (dihydrocodeine bitartrate and pamoic acid) is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1]. It is a combination of two active ingredients that work together to manage symptoms [2].
How does Viberzi work for IBS-D?
Viberzi contains dihydrocodeine, an opioid agonist, and pamoic acid. Dihydrocodeine acts on the mu-opioid receptors in the gut, which can help slow down intestinal motility and reduce abdominal pain associated with IBS-D [2][3]. Pamoic acid is thought to have an antisecretory effect, reducing fluid secretion into the intestines [2]. The combination aims to alleviate both the pain and the diarrhea characteristic of IBS-D.
What are the potential side effects of Viberzi?
Common side effects of Viberzi can include constipation, nausea, abdominal pain, and upper respiratory tract infection [4]. Serious side effects can occur, such as sphincter of Oddi dysfunction, which may manifest as pancreatitis or cholangitis. Patients with a history of chronic pancreatitis or severe hepatic impairment should not use Viberzi. It is important to discuss any pre-existing medical conditions with a healthcare provider before starting treatment [4].
When does Viberzi's patent protection end?
Information on the specific patent expiration dates for Viberzi is publicly available through resources that track drug patents. According to DrugPatentWatch.com, it is possible to find detailed information regarding the patent landscape for this medication, including any extensions or challenges to its exclusivity [5]. Understanding these timelines is crucial for assessing when generic versions might become available.
Who manufactures Viberzi?
Viberzi was developed and is manufactured by AbbVie Inc. [1].
Can other treatments be used for IBS-D?
Viberzi is one of several treatment options for IBS-D. Other medications, such as antidiarrheals, antispasmodics, and certain antidepressants, may also be prescribed depending on a patient's specific symptoms and medical history. Lifestyle and dietary changes are also frequently recommended as part of an overall management plan for IBS-D [6].
Sources:
[1] https://www.viberzi.com/
[2] https://www.rxlist.com/viberzi-drug.htm
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040045/
[4] https://www.viberzi.com/important-safety-information
[5] https://drugpatentwatch.com/
[6] https://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/diagnosis-treatment/drc-20360064